ACELYRIN, Inc.
SLRNDelisted May 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962918
ACELYRIN, Inc. was delisted on May 21, 2025; its insiders filed their last Form 4 on May 23, 2025; 106 institutions reported holding it in 13F filings for Q1 2025, worth $182.6M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 3:06 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 |
|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K |
| Reported | Feb 6, 2025 | Mar 28, 2024 |
| Operating expenses | $316.3M | $422.1M |
| Research and development | $238.1M | $355.9M |
| Selling, general and administrative | $66.8M | $66.2M |
| Operating income | -$316.3M | -$422.1M |
| Income tax | $0 | $0 |
| Net income | -$248.2M | -$381.6M |
| EPS, basic | $-2.50 | $-5.43 |
| EPS, diluted | $-2.50 | $-5.43 |
| Weighted shares, basic | 99.3M | 70.2M |
| Weighted shares, diluted | 99.3M | 70.2M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 |
|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K |
| Reported | Feb 6, 2025 | Mar 28, 2024 |
| Cash and equivalents | $73.9M | $218.1M |
| Total current assets | $481.0M | $736.6M |
| Property, plant and equipment | $1.64M | $2.18M |
| Total assets | $491.1M | $742.7M |
| Accounts payable | $4.89M | $41.9M |
| Total current liabilities | $26.6M | $85.2M |
| Total liabilities | $32.8M | $86.4M |
| Shareholders' equity | $458.3M | $656.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 |
|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K |
| Reported | Feb 6, 2025 | Mar 28, 2024 |
| Operating cash flow | -$303.9M | -$169.7M |
| Capital expenditures | $1.25M | $2.29M |
| Free cash flow | -$305.2M | -$172.0M |
| Depreciation and amortization | $423.0K | $115.0K |
| Stock-based compensation | $45.0M | $47.3M |
| Investing cash flow | $154.9M | -$447.7M |
| Financing cash flow | $5.39M | $568.4M |
| Net change in cash | -$143.7M | -$49.0M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.